The clinical impact of edoxaban for the patients with postoperative anemia after total hip arthroplasty

Izushi, Yasuhisa; Shiota, Naofumi; Tetsunaga, Tomonori; Shimada, Kenji; Egawa, Takashi; Kiuchi, Tsukasa; Satô, Tôru; Takuma, Ritsugi; Takami, Yoichiro

doi:10.1007/s00590-018-2212-0

Cited by 6 publications

(9 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the difference in Hb between groups was 0.1–0.6 g/dL, which is much less than a clinically important difference in Hb of 1.0–2.0 g/dL [27,28]. This finding is consistent with some previous reports, which showed that edoxaban administration after THA resulted in more anemia [7,8]. However, another study showed that prophylactic edoxaban administration after TKA did not increase the incidence of major or clinically relevant non-major bleeding [29].…”

Section: Discussionsupporting

confidence: 90%

“…Administration of 60 mg/day edoxaban resulted in a larger hemoglobin (Hb) drop than 10 mg/day apixaban administration for treatment of DVT after TKA or THA [7]. Prophylactic administration of 30 mg edoxaban after THA is associated with more anemia than administration of 2.5 mg fondaparinux [8]. However, Fuji et al reported that oral edoxaban 30 mg once daily was superior to subcutaneous enoxaparin 2000 IU twice daily for preventing VTE following THA without increasing the risk for major or clinically relevant non-major bleeding [9].…”

Section: Introductionmentioning

confidence: 99%

“…Several reports have compared the effect of edoxaban on D-dimer levels and the degree of anemia after total arthroplasty surgery [7,8,9,16]. However, no studies have evaluated the effect of edoxaban on D-dimer levels compared with no anticoagulant control after THA.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Does Prophylactic Administration of Edoxaban Increase D-Dimer Levels after Total Hip Arthroplasty?

Kawai

Kuroda

Goto

et al. 2019

JCM

View full text Add to dashboard Cite

This study aimed to examine the effect of thromboprophylactic edoxaban on D-dimer levels and anemia after total hip arthroplasty (THA). We retrospectively analyzed data from 349 patients undergoing primary THA. Univariate regression and multivariate regression analyses were performed with D-dimer levels on the 7th, 14th, and 21st days postoperatively as the dependent variable Edoxaban use, age, sex, body mass index (BMI), renal function, drop in hemoglobin (Hb) drop, intraoperative blood loss and duration of surgery as were independent variables. Multivariate regression analysis was also performed with Hb drop as the dependent variable. Edoxaban administration of 15 mg/day and 30 mg/day after THA was correlated with higher D-dimer levels at 21, but not at 7 or 14, days postoperatively. Other significant independent predictors for high D-dimer levels were the duration of surgery (at 7 and 14 days), BMI (at 7 days), sex (at 14 days), and age (at 14 and 21 days). Edoxaban use was significantly, weakly correlated with a larger Hb drop at 7 and 14 days, but this was less than a clinically important difference. D-dimer levels after THA can be elevated by thromboprophylactic edoxaban after three weeks postoperatively.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Does Prophylactic Administration of Edoxaban Increase D-Dimer Levels after Total Hip Arthroplasty?

Kawai

Kuroda

Goto

et al. 2019

JCM

View full text Add to dashboard Cite

show abstract

“…[ 10 , 11 ] Next, the risk factors for anemia in patients who underwent Edx treatment after surgery were retrospectively investigated in a case−control study as the secondary analysis of 2 previous studies. [ 5 , 6 ] Finally, the association of the detected risk factors for anemia with the hemoglobin (Hgb) levels, coagulation parameters, and transfusion during Edx treatment after surgery was investigated.…”

Section: Methodsmentioning

confidence: 99%

“…However, Edx treatment increased the frequency of anemia after TKA/THA compared with fondaparinux, the primary conventional anticoagulant, at only a single center. [ 5 , 6 ] Therefore, the risk of anemia with Edx treatment remains elusive. Additionally, no information is available regarding the risk factors for anemia before initiating Edx treatment.…”

Section: Introductionmentioning

confidence: 99%

The importance of renal function in anemic patients treated with edoxaban after orthopedic surgery in a real-world clinical setting: A retrospective study

et al. 2022

Self Cite

View full text Add to dashboard Cite

Edoxaban (Edx) has been approved to prevent venous thromboembolism after total knee and/or hip arthroplasty in Japan. However, the risk of anemia with Edx treatment remains elusive. No risk factors for Edx-associated anemia after orthopedic surgery have been reported. This study aimed to clarify the risk of anemia associated with Edx treatment and determine the risk factors for Edx-associated anemia after orthopedic surgery with a high risk for bleeding. First, the association between Edx treatment and the incidence of anemia-related events was retrospectively investigated by pharmacovigilance analyses using data from 5769,866 reports between the first quarters of 2016 and 2020 in the Food and Drug Administration Adverse Event Reporting System and 2752,050 reports between the fourth quarters of 2011 and 2019 in the Japanese Adverse Drug Event Report. Second, 221 patients who underwent Edx treatment after total knee and/or hip arthroplasty between July 2011 and June 2012 at a single center were included in a case−control study to clarify the risk factors for anemia. Edx treatment was associated with an increased risk of anemia-related events in orthopedic patients. Reduced renal function was identified as a critical risk factor for Edx-associated anemia after orthopedic surgery. The present study indicates that renal function should be considered in the risk management of increased Edx-associated anemia after orthopedic surgery.

show abstract

Different Coagulation Indicators in Predicting Clinical Outcomes for Patients With Direct Oral Anticoagulants: A Systematic Review and Meta-analysis

Liu

Zhang

Xie

et al. 2020

Clinical Therapeutics

View full text Add to dashboard Cite

The clinical impact of edoxaban for the patients with postoperative anemia after total hip arthroplasty

Cited by 6 publications

References 21 publications

Does Prophylactic Administration of Edoxaban Increase D-Dimer Levels after Total Hip Arthroplasty?

Does Prophylactic Administration of Edoxaban Increase D-Dimer Levels after Total Hip Arthroplasty?

The importance of renal function in anemic patients treated with edoxaban after orthopedic surgery in a real-world clinical setting: A retrospective study

Different Coagulation Indicators in Predicting Clinical Outcomes for Patients With Direct Oral Anticoagulants: A Systematic Review and Meta-analysis

Contact Info

Product

Resources

About